Burkhard L. Herrmann, Christian Berg, Elisabeth Vogel, Tanja Nowak, Katrin Renzing-Koehler, Klaus Mann, Bernhard Saller. Effects of a Combination of Recombinant Human Growth Hormone with Metformin on Glucose Metabolism and Body Composition in Patients with Metabolic Syndrome. February 2004 Hormone and Metabolic Research 36(1):54-61.
Abdominal obesity and insulin resistance are central findings in metabolic syndrome. Since treatment with recombinant human growth hormone (rhGH) can reduce body fat mass in patients with organic GH deficiency, rhGH therapy may also have favourable effects on patients with metabolic syndrome. However, due to the highly increased risk for type 2 diabetes in these patients, strategies are needed to reduce the antagonistic effect of rhGH against insulin. We conducted a 18-month randomised, double-blind, placebo-controlled study to assess the effect of rhGH in combination with metformin (Met) in patients with metabolic syndrome. 25 obese men (55 +/- 6 years, BMI 33.4 +/- 2.9 kg/m (2)) with mildly elevated fasting plasma glucose (FPG) levels at screening (6.1-8.0 mmol/l) were included. All patients received metformin (850 mg twice daily) either alone or in combination with rhGH (daily dose 9.5 microg/kg body weight). An oGTT was performed at baseline, after 6 weeks, and after 3, 6, 12, and 18 months of therapy. Glucose disposal rate (GDR) was measured by euglycemic hyperinsulinemic clamp at 0 and 18 months and body composition was measured by DEXA every 6 months. In the Met + GH group, IGF-I increased from 146 +/- 56 microg/l to 373 +/- 111 microg/l (mean +/- SD) after 3 months and remained stable after that. BMI did not change significantly in either group during the study. Total body fat decreased by -4.3 +/- 5.4 kg in the Met + GH group and by -2.7 +/- 2.9 kg in the Met + Placebo group (differences between the two groups: p = n. s.). Waist circumference decreased in both groups (Met + GH: 118 +/- 8 cm at baseline, 112 +/- 10 cm after 18 months; Met + Placebo: 114 +/- 7 cm vs. 109 +/- 8 cm; differences between the two groups: p = 0.096). In the Met + GH group, FPG increased significantly after 6 months (5.9 +/- 0.7 vs. 6.7 +/- 0.4 mmol/l; p = 0.005),but subsequently decreased to baseline levels (18 months: 5.8 +/- 0.2 mmol/l). FPG remained stable in the Met + Placebo group until 12 months had elapsed, and then slightly decreased (baseline: 6.2 +/- 0.3, 18 months: 5.5 +/- 0.6 mmol/l, p = 0.02). No significant changes were seen in either group regarding glucose and insulin AUC during oGTT or HbA (1c) levels. GDR at 18 months increased by 20 +/- 39% in Met + GH-group and decreased by -11 +/- 25% in the Met + Placebo group (differences between the two groups: p = 0.07). In conclusion, treatment of patients with metabolic syndrome and elevated FPG levels did not cause sustained negative effects on glucose metabolism or insulin sensitivity if given in combination with metformin. However, since our data did not show significant differences between the two treatment groups with respect to body composition or lipid metabolism, future studies including larger numbers of patients will have to clarify whether the positive effects of rhGH on cardiovascular risk factors that have been shown in patients with GH deficiency are also present in patients with metabolic syndrome, and are additive to the effects of metformin.
* Both groups received 850 mg Metformin/twice daily
* In the Met + hGH group, IGF-I increased, stabilized after 3 months, the Metformin + placebo group did not change
* Total body fat decreased in both groups, almost double in the hGH group
* Waist circumference decreased in both groups (more in the HGH group)
* After 18 months total muscle mass increased by 0.5 +/- 3.7 kg in the Met+GH group (range -4.6 to 3.7) and decreased by -2.4 _/- 2.9 in the
Met+Placebo group (range –5.7 to 2.2)
* Serum total testosterone levels significantly increased in both groups after 18 months
* Insulin levels did not significantly differ between those patients receiving only metformin and those receiving metformin and hGH
So in this study those doing hGH and Metformin actually increased IGF-levels those who only did Metformin had no change in IGF-1 levels.
i know for me, being T1D, when i take anything over 2iu of HGH, its wrecks my blood sugar. when I say it wrecks it, im talking no matter how much insulin i use, it wont go below 300 on the glucose meter. ive used well into 40ius of insulin and not eaten a thing with it and sugar remains. come of the HGH for a week and returns back to normal. recommend to use Met or Berberine. I started with berberine and it helped sig but good god, it was like shitting a brick, like a reinforced concrete block. metformin helped but cant get the Dr to Rx it bc not normal to have slin and Met. so my answer may not help but i can attest to the met and the berberine helping with the glucose resistance GH is known for
Reliable has 112 1000mg tabs for 65 bucks plus shipping
There are currently 0 members watching this topic